Elwyn C. Cabebe
Research Subjects
Elwyn C. Cabebe has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Lynn Dowling
Cancer Center at El Camino Hospital, Mountain View, CA, USA
2 shared publicationsMary Miller
Cancer Center at El Camino Hospital, Mountain View, CA, USA
2 shared publicationsRobert P. Young
University of Auckland, Auckland, New Zealand
2 shared publicationsShyamali Singhal
Cancer Center at El Camino Hospital, Mountain View, CA, USA
2 shared publicationsVincent K. Lam
University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA
2 shared publicationsBranimir I. Sikic
Stanford University School of Medicine
1 shared publication
Latest Publications
- 24 September 2019
- Published by Springer Nature in Lung
- Vol. 197 (5) , 685
Correction to: Community Low-Dose CT Lung Cancer Screening: A Prospective Cohort Study
The original version of this article contained an error in the usage of the term “false positive rate”. The intention of the authors in those instances was simply to compare the absolute percentage...
- 24 September 2019
- Published by Springer Nature in Lung
- Vol. 197 (5) , 685
Correction to: Community Low-Dose CT Lung Cancer Screening: A Prospective Cohort Study
The original version of this article contained an error in the usage of the term “false positive rate”. The intention of the authors in those instances was simply to compare the absolute percentage...
- 11 December 2014
- Published by Springer Nature in Lung
- Vol. 193 (1) , 135-139
Community Low-Dose CT Lung Cancer Screening: A Prospective Cohort Study
The National Lung Screening Trial (NLST) in 2011 showed that low-dose CT (LDCT) screening in high-risk groups reduces lung cancer deaths. Major professional organizations, as well as the U.S. Preventative Services Task Force, have endorsed LDCT screening in these select populations. However, major questions remain about whether widespread deployment of CT screening can achieve results similar to the NLST, especially in the community setting. A prospective cohort study was initiated in November 2010. Participants at least 50 years old and with at least 20 pack-years of smoking history underwent LDCT screening in a community setting. One hundred and fifty four participants underwent LDCT screening with median follow-up of 2.7 years. Compared with the NLST, there was a higher rate of positive screening tests (35.7 vs. 27.3 %), higher false positive rate (100 vs. 96.4 %), and poor adherence (43 vs. 95 %). Invasive diagnostic follow-up was uncommon and uncomplicated. No interval lung cancer was detected. Late follow-up was mostly attributed to participant or primary care provider preference (67.5 %), participants lost to follow-up (17.5 %), and lack of insurance (10 %). These findings highlight the potential challenges of generalizing the NLST mortality benefits in the broad deployment of CT screening. Our results support current recommendations that LDCT screening be performed in a highly structured and integrated setting.
- 11 December 2014
- Published by Springer Nature in Lung
- Vol. 193 (1) , 135-139
Community Low-Dose CT Lung Cancer Screening: A Prospective Cohort Study
The National Lung Screening Trial (NLST) in 2011 showed that low-dose CT (LDCT) screening in high-risk groups reduces lung cancer deaths. Major professional organizations, as well as the U.S. Preventative Services Task Force, have endorsed LDCT screening in these select populations. However, major questions remain about whether widespread deployment of CT screening can achieve results similar to the NLST, especially in the community setting. A prospective cohort study was initiated in November 2010. Participants at least 50 years old and with at least 20 pack-years of smoking history underwent LDCT screening in a community setting. One hundred and fifty four participants underwent LDCT screening with median follow-up of 2.7 years. Compared with the NLST, there was a higher rate of positive screening tests (35.7 vs. 27.3 %), higher false positive rate (100 vs. 96.4 %), and poor adherence (43 vs. 95 %). Invasive diagnostic follow-up was uncommon and uncomplicated. No interval lung cancer was detected. Late follow-up was mostly attributed to participant or primary care provider preference (67.5 %), participants lost to follow-up (17.5 %), and lack of insurance (10 %). These findings highlight the potential challenges of generalizing the NLST mortality benefits in the broad deployment of CT screening. Our results support current recommendations that LDCT screening be performed in a highly structured and integrated setting.
- 15 March 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (3) , 1082-1087
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Background Vandetanib is a tyrosine kinase inhibitor of both the vascular endothelial growth factor (VEGFR) and epidermal growth factor (EGFR) receptors. The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities. Materials and methods Three cohorts of patients were studied, with capecitabine at 1,000 mg/m2 twice daily p.o. on days 1–14 of a 3 week cycle, with oxaliplatin i.v. at 130 mg/m2 on day 1. Vandetanib dosing was 100 mg/day in cohort 1 and 300 mg/day in cohorts 2 and 3. Bevacizumab was added in cohort 3 at 7.5 mg/kg IV on day 1 every 3 weeks. Results Thirteen patients were enrolled and received from one to eight cycles per patient. Grade 4 dermatitis developed in one patient in the first cohort, and the cohort was expanded to six patients with no further dose limiting toxicities (DLT). The second cohort of 3 patients was well tolerated. The third cohort resulted in grade 3 diarrhea, requiring several days of hospitalization and IV hydration, in 3 of the 4 patients. Given the severity and duration of diarrhea, each of these was considered a DLT, and therefore cohort 3 was considered to be above the maximum tolerated dose. Six of the 13 patients achieved a partial or complete remission (46%). The time to progression ranged from 2 to 14 months. Conclusions Vandetanib at doses of 100 mg and 300 mg daily in combination with capecitabine and oxaliplatin was well tolerated. However, the addition of bevacizumab resulted in severe diarrhea in three out of four patients. Bevacizumab was not well tolerated with vandetanib and XELOX in combination.
- 15 March 2011
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (3) , 1082-1087
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Background Vandetanib is a tyrosine kinase inhibitor of both the vascular endothelial growth factor (VEGFR) and epidermal growth factor (EGFR) receptors. The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities. Materials and methods Three cohorts of patients were studied, with capecitabine at 1,000 mg/m2 twice daily p.o. on days 1–14 of a 3 week cycle, with oxaliplatin i.v. at 130 mg/m2 on day 1. Vandetanib dosing was 100 mg/day in cohort 1 and 300 mg/day in cohorts 2 and 3. Bevacizumab was added in cohort 3 at 7.5 mg/kg IV on day 1 every 3 weeks. Results Thirteen patients were enrolled and received from one to eight cycles per patient. Grade 4 dermatitis developed in one patient in the first cohort, and the cohort was expanded to six patients with no further dose limiting toxicities (DLT). The second cohort of 3 patients was well tolerated. The third cohort resulted in grade 3 diarrhea, requiring several days of hospitalization and IV hydration, in 3 of the 4 patients. Given the severity and duration of diarrhea, each of these was considered a DLT, and therefore cohort 3 was considered to be above the maximum tolerated dose. Six of the 13 patients achieved a partial or complete remission (46%). The time to progression ranged from 2 to 14 months. Conclusions Vandetanib at doses of 100 mg and 300 mg daily in combination with capecitabine and oxaliplatin was well tolerated. However, the addition of bevacizumab resulted in severe diarrhea in three out of four patients. Bevacizumab was not well tolerated with vandetanib and XELOX in combination.